Mereo BioPharma Group plc
MREO
$2.74
$0.2811.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 1.00M | 1.00M | 10.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 1.00M | 1.00M | 10.00M |
| Cost of Revenue | -- | -- | -273.00K | -508.00K | 2.92M |
| Gross Profit | -- | -- | 1.27M | 1.51M | 7.08M |
| SG&A Expenses | 27.80M | 26.43M | 23.57M | 23.08M | 17.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.31M | 45.71M | 39.07M | 38.90M | 35.65M |
| Operating Income | -47.31M | -45.71M | -38.07M | -37.90M | -25.65M |
| Income Before Tax | -47.19M | -43.25M | -45.85M | -37.38M | -26.87M |
| Income Tax Expenses | -- | -- | -532.00K | -532.00K | -532.00K |
| Earnings from Continuing Operations | -47.19 | -43.25 | -45.32 | -36.85 | -26.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.19M | -43.25M | -45.32M | -36.85M | -26.34M |
| EBIT | -47.31M | -45.71M | -38.07M | -37.90M | -25.65M |
| EBITDA | -46.73M | -45.13M | -37.48M | -37.31M | -25.04M |
| EPS Basic | -1.56 | -1.46 | -1.56 | -1.31 | -0.95 |
| Normalized Basic EPS | -0.19 | -0.18 | -0.20 | -0.17 | -0.12 |
| EPS Diluted | -1.56 | -1.46 | -1.56 | -1.31 | -0.95 |
| Normalized Diluted EPS | -0.19 | -0.18 | -0.20 | -0.17 | -0.12 |
| Average Basic Shares Outstanding | 608.25M | 591.45M | 576.40M | 559.37M | 542.70M |
| Average Diluted Shares Outstanding | 121.65M | 118.29M | 115.28M | 111.87M | 108.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |